Use of integrin alpha 6 transcripts in a stool mRNA assay for the detection of colorectal cancers at curable stages

Oncotarget

Volumn 7, Issue 12, 2016, Pages 14684-14692

  Beaulieu, Jean François ^a   Herring, Elizabeth ^a   Kanaoka, Shigeru ^b   Tremblay, Éric ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b HAMAMATSU MEDICAL CENTER   (Japan)

Author keywords

Adenomas; Biomarker; Colorectal cancer; Mrna; Non invasive screening

Indexed keywords

ALPHA6 INTEGRIN; MESSENGER RNA; ITGA6 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FECES ANALYSIS; FEMALE; GADD45B GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE TARGETING; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; ITGA6 GENE; MAJOR CLINICAL STUDY; MALE; MYBL2 GENE; OCCULT BLOOD; ONCOGENE; ONCOGENE MYC; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; CHEMISTRY; COHORT ANALYSIS; COLORECTAL TUMOR; EARLY CANCER DIAGNOSIS; FECES; GENETICS; MIDDLE AGED; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COHORT STUDIES; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FEMALE; HUMANS; INTEGRIN ALPHA6; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; ROC CURVE;

EID: 84962888140     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7407     Document Type: Article

References (36)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10-29.
2. Willyard C. Screening: Early alert. Nature. 2015; 521:S4-5.
3. Robertson DJ and Imperiale TF. Stool Testing for Colorectal Cancer Screening. Gastroenterology. 2015; 149:1286-1293.
4. Maratt JK and Saini SD. Colorectal cancer screening in the 21st century: where do we go from here? Am J Manag Care. 2015; 21:e447-449.
5. Allison JE, Fraser CG, Halloran SP and Young GP. Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver. 2014; 8:117-130.
6. Wong MC, Ching JY, Chan VC, Lam TY, Shum JP, Luk AK, Wong SS, Ng SC, Ng SS, Wu JC, Chan FK and Sung JJ. Diagnostic Accuracy of a Qualitative Fecal Immunochemical Test Varies With Location of Neoplasia But Not Number of Specimens. Clin Gastroenterol Hepatol. 2015; 13:1472-1479.
7. Chiu HM, Lee YC, Tu CH, Chen CC, Tseng PH, Liang JT, Shun CT, Lin JT and Wu MS. Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol. 2013; 11:832-838 e831-832.
8. Lee JK, Liles EG, Bent S, Levin TR and Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014; 160:171.
9. Blanks RG, Benson VS, Alison R, Brown A, Reeves GK, Beral V, Patnick J and Green J. Nationwide bowel cancer screening programme in England: cohort study of lifestyle factors affecting participation and outcomes in women. Br J Cancer. 2015; 112:1562-1567.
10. Ricardo-Rodrigues I, Hernandez-Barrera V and Jimenez-Garcia R. Awareness of colonoscopy as a screening method for colorectal cancer and its uptake in Spain. Eur J Cancer Prev. 2014; 23:398-404.
11. Raginel T, Puvinel J, Ferrand O, Bouvier V, Levillain R, Ruiz A, Lantieri O, Launoy G and Guittet L. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. Gastroenterology. 2013; 144:918-925.
12. Hundt S, Haug U and Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 2009; 150:162-169.
13. Ahnen DJ, Bresalier RS, Levin B and Kaunitz JD. CRC screening, past, present, and future: a tribute to Emmet Keeffe. Dig Dis Sci. 2015; 60:589-591.
14. Pawa N, Arulampalam T and Norton JD. Screening for colorectal cancer: established and emerging modalities. Nat Rev Gastroenterol Hepatol. 2011; 8:711-722.
15. Di Lena M, Travaglio E and Altomare DF. New strategies for colorectal cancer screening. World J Gastroenterol. 2013; 19:1855-1860.
16. Cekaite L, Eide PW, Lind GE, Skotheim RI and Lothe RA. MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget. 2015. Nov 25. doi: 10.18632/oncotarget.6390. PMID: 26623728.
17. Kanaoka S, Yoshida K, Miura N, Sugimura H and Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology. 2004; 127:422-427.
18. Takai T, Kanaoka S, Yoshida K, Hamaya Y, Ikuma M, Miura N, Sugimura H, Kajimura M and Hishida A. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2009; 18:1888-1893.
19. Yau TO, Wu CW, Tang CM, Chen Y, Fang J, Dong Y, Liang Q, Ng SS, Chan FK, Sung JJ and Yu J. microRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer. Oncotarget. 2016; 7:1559-68. doi: 10.18632/oncotarget.6403.
20. Hamaya Y, Yoshida K, Takai T, Ikuma M, Hishida A and Kanaoka S. Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer. Br J Cancer. 2010; 102:916-921.
21. Ahlquist DA, Harrington JJ, Burgart LJ and Roche PC. Morphometric analysis of the 'mucocellular layer' overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol. 2000; 31:51-57.
22. Yu YJ, Majumdar AP, Nechvatal JM, Ram JL, Basson MD, Heilbrun LK and Kato I. Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis of biomarkers of gastrointestinal cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17:455-458.
23. Koga Y, Yasunaga M, Katayose S, Moriya Y, Akasu T, Fujita S, Yamamoto S, Baba H and Matsumura Y. Improved recovery of exfoliated colonocytes from feces using newly developed immunomagnetic beads. Gastroenterol Res Pract. 2008; 2008:605273.
24. Rengucci C, De Maio G, Menghi M, Scarpi E, Guglielmo S, Fusaroli P, Caletti G, Saragoni L, Casadei Gardini A, Zoli W, Falcini F, Amadori D and Calistri D. Improved stool DNA integrity method for early colorectal cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 2014; 23:2553-2560.
25. Calistri D, Rengucci C, Lattuneddu A, Francioni G, Polifemo AM, Nanni O, Saragoni L, Monti F, Ravaioli A, Zoli W and Amadori D. Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool. Neoplasia. 2004; 6:536-540.
26. Dydensborg AB, Teller IC, Groulx JF, Basora N, Pare F, Herring E, Gauthier R, Jean D and Beaulieu JF. Integrin alpha6Bbeta4 inhibits colon cancer cell proliferation and c-Myc activity. BMC Cancer. 2009; 9:223.
27. Groulx JF, Giroux V, Beausejour M, Boudjadi S, Basora N, Carrier JC and Beaulieu JF. Integrin alpha6A splice variant regulates proliferation and the Wnt/beta-catenin pathway in human colorectal cancer cells. Carcinogenesis. 2014; 35:1217-1227.
28. Ni H, Dydensborg AB, Herring FE, Basora N, Gagné D, Vachon PH and Beaulieu J-F. Upregulation of a functional form of the beta4 integrin subunit in colorectal cancers correlates with c-Myc expression. Oncogene. 2005; 24:6820-6829.
29. Dydensborg AB, Herring E, Auclair J, Tremblay E and Beaulieu J-F. Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol. 2006; 290:G1067-1074.
30. Ng EW, Poon TC, Lam HS, Cheung HM, Ma TP, Chan KY, Wong RP, Leung KT, Lam MM, Li K and Ng PC. Gut-associated biomarkers L-FABP, I-FABP, and TFF3 and LIT score for diagnosis of surgical necrotizing enterocolitis in preterm infants. Ann Surg. 2013; 258:1111-1118.
31. Meijer GA. What makes CRCs metastasise? Gut. 2010; 59:1164-1165.
32. Frisch SM and Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994; 124:619-626.
33. Imperiale TF, Ransohoff DF and Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014; 371:187-188.
34. You YN, Rustin RB and Sullivan JD. Oncotype DX((R)) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence. Surg Oncol. 2015; 24:61-66.
35. Leung WK, To KF, Man EP, Chan MW, Hui AJ, Ng SS, Lau JY and Sung JJ. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol. 2007; 102:1070-1076.
36. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S and Denkert C. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012; 7:e51862.